跳至主要内容
临床试验/NCT01212601
NCT01212601已完成不适用

A Multicenter, Observational, Non-interventional Registry Designed to Collect Clinical Data in Chinese Patients Who Have Received CUBICIN® Treatment Under Condition of Actual Usage in Clinical Practice

AstraZeneca1 个研究点 分布在 1 个国家目标入组 203 人开始时间: 2011年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
203
试验地点
1
主要终点
AEs of CUBICIN therapy

研究概览

简要总结

This is a Multicenter, observational, non-interventional registry designed to collect clinical data in Chinese patients who have received CUBICIN treatment under condition of actual usage in clinical practice.

详细描述

MC MD

研究设计

研究类型
Observational
观察模型
Cohort

入排标准

性别
All
接受健康志愿者

入选标准

  • Patient has received CUBICIN treatment, decided by treating physician
  • A patient who is considered as ethnic Chinese
  • Provision of subject informed consent

排除标准

  • A patient record will not be eligible for the registry database if the patient received CUBICIN as part of a controlled clinical study for the current infection episode.

结局指标

主要结局

AEs of CUBICIN therapy

时间窗: 2 weeks

clinical response of CUBICIN therapy at each available time point

时间窗: 2 weeks

次要结局

  • CPK level monitoring and results(2 weeks)
  • treatment duration(2 weeks)
  • Time to clinical response(2 weeks)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Collect Clinical Data in Chinese Patients Received... | 临床试验